ClinicalTrials.gg
CompletedNCT03499223Updated Aug 2, 2019

A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)

A Phase 2 interventional study of Ranibizumab 0.5mg and THR-317 8mg in Diabetes Mellitus, Diabetic Retinopathy and Macular Edema, sponsored by Oxurion. Completed at 37 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-02.

Primary conditionDiabetic RetinopathyRegistry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetic Retinopathy
Why
  1. The study's listed conditions name Diabetic Retinopathy, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Oxurion · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Diabetic Retinopathy with a site in France — 5 open to participants now, 5 under way, none of them phase 3. Diabetic Retinopathy · France.

Enrollment
13th of 19
70 · median 135
Started
2018
with 2 others
Phase 2
4 of 30
none open now
Registered
17th of 30
by date
Lead sponsor
2 of 30
Oxurion

Among the 30 studies in Diabetic Retinopathy with a site in France, this one is the 13th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2018, is one of 4 in phase 2, and was the 17th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

5 of the 30 studies in Diabetic Retinopathy with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Diabetic Retinopathy with a site in France, or all of them as a file.
02

Study summary

This study is conducted to evaluate the safety of intravitreal THR-317 administered in combination with ranibizumab, and to assess the efficacy of the combination treatment in improving best-corrected visual acuity (BCVA) and reducing central subfield thickness (CST), in subjects with central-involved diabetic macular oedema (CI-DME).

03

Conditions studied

  • Diabetes Mellitus
  • Diabetic Retinopathy
  • Macular Edema

Browse trials for

04

In context

Diabetic Retinopathy Reclassified

783 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

This study's enrollment of 70 is below the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.

Browse Diabetic Retinopathy studies →

Lead sponsor

Oxurion is the lead sponsor of 3 studies on the registry; none are open to participants now.

Compared within Diabetic Retinopathy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 years or older
  • Type 1 or type 2 Diabetes Mellitus
  • CI-DME with central subfield thickness of ≥ 320μm on Spectralis® SD-OCT or ≥ 305μm on non Spectralis SD-OCT, in the study eye
  • Anti-vascular endothelial growth factor (anti-VEGF) treatment naïve study eye, or poor or no response to prior treatment with ranibizumab in the study eye
  • Reduced vision primarily due to DME, with BCVA ≤ 72 and ≥ 23 ETDRS letter score (≤ 20/40 and ≥ 20/320 Snellen equivalent) in the study eye
  • Non-proliferative diabetic retinopathy of any stage in the study eye
  • Written obtained from the subject prior to screening procedures

Exclusion criteria

Exclusion Criteria:

  • Concurrent disease in the study eye, other than CI-DME, that could compromise BCVA, require medical or surgical intervention during the study period or could confound interpretation of the results
  • Previous confounding treatments / procedures, or their planned / expected use during the study period for up to 30 days after the last administration of study treatment
  • Any active ocular / intraocular infection or inflammation in either eye
  • Aphakic study eye
  • Poorly controlled Diabetes Mellitus
  • Uncontrolled hypertension
  • Pregnant or lactating female, or female of not utilising an adequate form of , or male of not utilising contraception
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Ranibizumab + THR-317

    Subjects will receive intravitreal ranibizumab in combination with THR-317

    Drug: Ranibizumab 0.5mg · Drug: THR-317 8mg

  • Active comparator
    Sham + ranibizumab

    Subjects will receive a sham injection in combination with intravitreal ranibizumab

    Drug: Ranibizumab 0.5mg · Drug: Sham injection

Interventions

  • DrugRanibizumabStudies of RanibizumabRanibizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3 intravitreal injections of ranibizumab 0.5mg, approximately 1 month apart

    Also known as: Lucentis®

  • DrugTB-403Studies of TB-403TB-403 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3 intravitreal injections of THR-317 8mg, approximately 1 month apart

  • DrugSham injection

    3 sham injections, approximately 1 month apart. No actual injections. No medication is used.

07

What researchers measure

Primary outcomes

  1. Change from baseline in BCVA

    Time frame: At Day 84 (Month 3)

Secondary outcomes

  1. Incidence of systemic and ocular adverse events including serious adverse events

    Time frame: From Day 0 to Day 140

  2. Change from baseline in BCVA, by study visit

    Time frame: From Day 0 to Day 140

  3. Change from baseline in CST, based on spectral domain optical coherence tomography (SD-OCT), as assessed by the central reading centre, by study visit

    Time frame: From Screening to Day 140

  4. Withdrawal from repeat study treatment and reason for withdrawal

    Number of subjects meeting withdrawal criteria from repeat study treatment

    Time frame: At Day 28 and at Day 56

08

Study locations

37 sites
  • CHU Brugmann
    Brussels, 1020, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Centre Rétine Gallien
    Bordeaux, 33000, France
  • Centre Hospitalier Intercommunal de Créteil
    Créteil, 94010, France
  • CHU Dijon
    Dijon, 21079, France
  • Hôpital Privé La Louvière
    Lille, 59800, France
  • Hôpital de la Croix Rousse
    Lyon, 69004, France
  • Hôpital Saint-Joseph
    Marseille, 13285, France
  • Centre Hospitalier Universitaire de Nice, Hôpital Pasteur
    Nice, 06001, France
  • Centre Ophtalmologique de l'Odéon
    Paris, 75006, France
  • Hôpital Lariboisière
    Paris, 75475, France
  • Centre Ophtalmologique Maison Rouge
    Strasbourg, 67000, France
  • Charite Universitaetsmedizin Berlin
    Berlin, 12203, Germany
  • Universitaetsklinikum Dresden
    Dresden, 01307, Germany
  • Universitaetsklinikum Frankfurt
    Frankfurt am Main, 60590, Germany
  • Universitaetsklinikum Leipzig
    Leipzig, 04103, Germany
  • Klinikum der Stadt Ludwigshafen am Rhein
    Ludwigshafen am Rhein, 67063, Germany
  • Philipps-Universität Marburg
    Marburg, 35043, Germany
  • Univerzitná nemocnica Bratislava, Nemocnica Ružinov
    Bratislava, 826 06, Slovakia
  • Univerzitná nemocnica Bratislava, Nemocnica Sv. Cyrila a Metoda
    Bratislava, 851 07, Slovakia
  • Nemocnica Poprad, a.s.
    Poprad, 058 01, Slovakia
  • Fakultná nemocnica Trenčín
    Trenčín, 911 71, Slovakia
  • Fakultná nemocnica s polikliniku Žilina
    Žilina, 012 07, Slovakia
  • Centro Médico Téknon
    Barcelona, 08022, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08028, Spain
  • Hospital general de Cataluña
    Barcelona, 08195, Spain
  • Hospital Universitari de Bellvitge
    L'Hospitalet De Llobregat, 08907, Spain
  • Vissum Madrid
    Madrid, 28002, Spain
  • Hospital General Universitario de Valencia
    Valencia, 46014, Spain
  • Oftalvist IMED Valencia
    Valencia, 46100, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • RétinElysée
    Lausanne, 1006, Switzerland
  • Royal Surrey County Hospital NHS Foundation Trust
    Guildford, GU2 7XX, United Kingdom
  • Leeds Teaching Hospitals NHS Trust
    Leeds, LS9 7TF, United Kingdom
  • Moorfields Eye Hospital NHS Foundation Trust
    London, EC1V 2PD, United Kingdom
  • Kings College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
  • City Hospitals Sunderland NHS Foundation Trust
    Sunderland, SR2 9HP, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Jul 2019, 14 months.

Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's 14 months is below that.

Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2018
First posted
Apr 17, 2018
StartActual
Apr 20, 2018
Primary completionActual
Jul 18, 2019
CompletionActual
Jul 18, 2019
Last update
Aug 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03499223
Lead sponsor
Oxurion
Responsible party
Sponsor
First posted
Apr 17, 2018
Start date
Apr 20, 2018
Primary completion
Jul 18, 2019
Completion
Jul 18, 2019
Last update
Aug 2, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TB-403

Start the discussion